29%) developed protective antibody
titer after receiving their 4th dose of vaccine compared with other trials done by Goyal et al.
The minimal protective antibody
amount has not been defined, but several lines of evidence suggest that it is <10 mIU/mL.
Pretravel titers of [greater than or equal to] 40 for [greater than or equal to] 1 influenza viruses were defined as protective antibody
The study led by Octavio Ramilo, MD, chief of Infectious Diseases and an investigator in the Center for Vaccines and Immunity at Nationwide Children's Hospital and professor of Pediatrics at The Ohio State University (OSU) College of Medicine, and Hideki Ueno, MD, PhD, an investigator at the Baylor Institute for Immunology Research at Baylor University, demonstrated how certain T cells in the blood are stimulated to provide protective antibody
responses with seasonal flu vaccines.
An estimated 90%-95% of healthy adults aged 40 years and younger achieve a protective antibody
titer (defined as anti-hepatitis B surface antigen concentrations of 10 mIU/mL or greater) after receiving the three-dose series (MMWR2011;60[RR07]:l-45).
A protective antibody
response takes about 2 weeks to develop.
At the highest dose tested, the coadministered vaccine produced protective antibody
titers in 88% of subjects after a single immunization.
Of the 25 babies born to women who responded to the vaccine, 80 percent had protective antibody
levels at 1 month of age and 64 percent had them at 3 months.
DNA vaccine induces protective antibody
and T-cell immune responses in non-human primates against Chikungunya virus
Affinity selection with Humabs' antibodies will lead to the production of VLPs that induce high-titer, durable, and protective antibody
responses that mimic the selecting therapeutic monoclonal antibody.
In these trials, a single dose of the vaccine containing 15 micrograms of the influenza hemagglutinin molecule-the main target of the protective antibody
response-was found to be well tolerated and induced a strong immune response in most participants.
This early spike in antibody is evidence of immune memory, whereby the immune system is able to kick in and provide the needed protection upon exposure to hepatitis B, even though the level of protective antibody
in a vaccinated person declines with time.
None of the identified broadly protective antibody
populations has been found consistently and at appropriate concentrations in human sera, which indicates that neither is effectively induced by natural
The recommended course of three doses of hepatitis B vaccine induces protective antibody
responses in 90% of healthy adults and in 95% of infants, children and adolescents.
The development of new, complementary therapeutic approaches, such as recombinant vaccines and broadly protective antibody
therapeutics, is a high international public health priority.